16 April 2022>: Database Analysis
Identification of Novel Genes and Associated Drugs in Cervical Cancer by Bioinformatics Methods
Dan Wang 1CDE , Yanling Liu 2F , Shuyu Cheng 1D , Guoyan Liu 123AG*DOI: 10.12659/MSM.934799
Med Sci Monit 2022; 28:e934799
Table 2 The significant drugs targeted to AURKA.
Drug ID | Drug name | Drug group | Confidence score |
---|---|---|---|
DB12010 | Fostamatinib | Approved; Investigational | 1 |
DB08896 | Regorafenib | Approved | 0.4247 |
DB01254 | Dasatinib | Approved; Investigational | 0.4221 |
DB12267 | Brigatinib | Approved; Investigational | 0.3649 |
DB08901 | Ponatinib | Approved; Investigational | 0.3572 |
DB06589 | Pazopanib | Approved | 0.3339 |
DB00398 | Sorafenib | Approved; Investigational | 0.3319 |
DB00619 | Imatinib | Approved | 0.3291 |
DB09079 | Nintedanib | Approved | 0.3128 |
DB00945 | Acetylsalicylic acid | Approved; Vet approved | 0.3053 |
DB01268 | Sunitinib | Approved; Investigational | 0.2983 |
DB06616 | Bosutinib | Approved | 0.279 |
DB00675 | Tamoxifen | Approved | 0.2778 |
DB08912 | Dabrafenib | Approved; Investigational | 0.2668 |
DB05294 | Vandetanib | Approved | 0.2632 |
DB09078 | Lenvatinib | Approved; Investigational | 0.2557 |
DB08875 | Cabozantinib | Approved; Investigational | 0.2384 |
DB11817 | Baricitinib | Approved; Investigational | 0.2319 |
DB06626 | Axitinib | Approved; Investigational | 0.2307 |
DB08895 | Tofacitinib | Approved; Investigational | 0.2201 |
DB06595 | Midostaurin | Approved; Investigational | 0.2168 |